Business
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
SOUTH SAN FRANCISCO, Calif., January 08, 2026--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that, on January 7, 2026, it entered into a loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (Avenue Capital), for up to $50 million in growth capital.
About this update from Spruce Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1175,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/02c4d1cffd891f0e3188aa0f441b9a20"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Df5As3kSfZI6q9tW.7HmnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/02c4d1cffd891f0e3188aa0f441b9a20","width":960,"height":310},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/GvuzTIgPoGvicjTzuLy12w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNTA7aD03NjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/02c4d1cffd891f0e3188aa0f441b9a20","width":1175,"height":380}},"lazy":false},{"type":"text","content":"Initial Funding of $15 Million from the First of Four Tranches, Extending Cash Runway into 2027","length":95,"tagName":"p","attribs":{}},{"type":"text","content":"Facility Will Support Advancement and Potential Launch of TA-ERT for the Treatment of MPS IIIB","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., January 08, 2026--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that, on January 7, 2026, it entered into a loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group (Avenue Capital), for up to $50 million in growth capital.","length":487,"tagName":"p"},{"type":"text","content":"The loan facility has a 42-month term and includes an initial tranche of $15 million, which will be fully funded on or around January 9, 2026, and three additional tranches totaling up to $35 million, the funding of which is subject to the satisfaction of certain terms and conditions of the loan and security agreement, including the achievement of key regulatory and commercial milestones related to the company’s development and planned commercial launch of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfillipo Syndrome Type B (MPS IIIB).","length":575,"tagName":"p"},{"type":"text","content":""We are pleased to partner with Avenue Capital on a strategic financing agreement with attractive terms that strengthens o...